X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution
- PMID: 19616557
- DOI: 10.1016/j.jmb.2009.07.027
X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution
Abstract
The S138A substitution of fusion inhibitory peptides derived from the C-terminal heptad repeat (C-HR) of the human immunodeficiency virus type 1 (HIV-1) gp41 leads to enhanced binding affinity to the N-terminal heptad repeat (N-HR). As such, these peptides exhibit highly potent anti-HIV-1 activity. X-ray crystallographic analysis was performed to understand the effect of the substitution on binding affinity. The comparison of the native and S138A crystal structures indicated that the increase in the hydrophobicity of the S138A substitution may aid the stabilization of the N-HR/C-HR complex through additional hydrophobic contacts. Free-energy calculations suggest that the difference between the desolvation free energies of the C-HR-derived peptides with and without the S138A mutation dominates the observed difference in anti-HIV-1 activity.
Similar articles
-
Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.Biochemistry. 2007 Apr 10;46(14):4360-9. doi: 10.1021/bi7001289. Epub 2007 Mar 20. Biochemistry. 2007. PMID: 17371053
-
Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.Antiviral Res. 2010 Aug;87(2):179-86. doi: 10.1016/j.antiviral.2010.04.011. Epub 2010 May 8. Antiviral Res. 2010. PMID: 20438763
-
Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41.Virology. 2010 Sep 15;405(1):157-64. doi: 10.1016/j.virol.2010.06.012. Epub 2010 Jul 2. Virology. 2010. PMID: 20580393
-
Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.Biochem Biophys Res Commun. 2000 Mar 24;269(3):641-6. doi: 10.1006/bbrc.1999.1972. Biochem Biophys Res Commun. 2000. PMID: 10720469 Review.
-
Qadirvirtide.Pak J Pharm Sci. 2011 Oct;24(4):593-5. Pak J Pharm Sci. 2011. PMID: 21959827 Review.
Cited by
-
HIV-1 envelope accessible surface and polarity: clade, blood, and brain.Bioinformation. 2011 Mar 22;6(2):48-56. doi: 10.6026/97320630006048. Bioinformation. 2011. PMID: 21544164 Free PMC article.
-
Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Viruses. 2012 Dec;4(12):3859-911. doi: 10.3390/v4123859. Viruses. 2012. PMID: 23342377 Free PMC article. Review.
-
Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.J Biol Chem. 2010 Dec 10;285(50):39471-80. doi: 10.1074/jbc.M110.145789. Epub 2010 Oct 11. J Biol Chem. 2010. PMID: 20937812 Free PMC article.
-
Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.J Biol Chem. 2009 Feb 20;284(8):4914-20. doi: 10.1074/jbc.M807169200. Epub 2008 Dec 10. J Biol Chem. 2009. PMID: 19073606 Free PMC article.
-
Origins of resistance to the HIVgp41 viral entry inhibitor T20.Biochemistry. 2010 May 4;49(17):3575-92. doi: 10.1021/bi901915g. Biochemistry. 2010. PMID: 20230061 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Research Materials